Cell Therapy

We are delighted to be working with innovative companies and academic institutions in the exciting field of cell therapy. We leverage our huge depth of experience in the fields of monoclonal antibody technology, cellular biology, immunology and regenerative medicine to build robust, investable patent portfolios for our clients in this space. While applying our wealth of existing knowledge, we are also alive to the fact that new technologies require fresh thinking and an innovative approach to patent protection.

We understand the importance of considering the practicalities of the production and administration of the therapeutic agent(s) at the earliest possible stage, and work with closely with our clients to understand that fine details of the technology and develop an appropriate supporting global patent strategy. For example, in the field of adoptive cellular therapy, strategy for protecting an autologous cell therapy, in which the therapeutic ‘product’ to be administered is a personalised product derived from a patient’s own cells requires a different approach to protecting an allogeneic cell therapy (towards which the field is increasingly moving), which in some aspects is closer to a traditional ‘off-the-shelf’ product.

We have considerable experience in drafting and prosecuting patent applications relating to innovative cell therapies, including for novel CAR/TCR molecules, new platform approaches and innovations relating to the production, expansion and medical use of cell therapies. As earlier generation products continue to mature through clinical trials, we also help our clients to protect innovation throughout the product lifecycle, for example with patent applications related to personalised medicine or new dosage regimes. We also help our clients to navigate the dynamic and increasingly complex patent landscape in the field of cell therapy, strategising with them to minimize the risk presented by patents held by third parties.

Mewburn Ellis is very proud to be working with the entities operating right at the cutting edge of innovation in this exciting field, developing the new platform technologies, designing novel recombinant molecules (CARs, TCRs, etc.) and moving into new disease frontiers (solid cancers, autoimmune disease, viral disease), that will re-shape the therapeutic landscape for the years to come.

Open Pages of Validation Strategies for Pharmaceutical Patents in Europe Report

Validation Strategies for Pharmaceutical Patents in Europe

Special Report

The decision on where to validate a pharmaceutical European patent is a big one. With costs often precluding an “everywhere” approach for small- to medium-sized companies, research institutions and universities, it is necessary to choose from the long list of available countries. The choice typically factors in costs, business interests, likely markets and market size, possible manufacturing and import locations and the regulatory framework in Europe.

This report explores these choices and factors using publicly available data, seeking to answer questions such as:

  • Which countries are most commonly picked by patent holders at the EPO?
  • Is the distribution the same for pharmaceutical patents?
  • Where does “big pharma” choose to validate?
  • What factors might affect the choice of countries?
DOWNLOAD THE REPORT

Read our blogs

UPC Weekly - Very appealing – preliminary injunction overturned

UPC Weekly - Very appealing – preliminary injunction overturned

by Matthew Naylor

2024 Week 49 SharkNinja have managed to persuade the UPC Court of Appeal to overturn a preliminary injunction awarded to Dyson. We investigate what made the difference in the appeal and consider what ...

UPC Weekly - Front-loading and obviousness at the UPC

UPC Weekly - Front-loading and obviousness at the UPC

by Matthew Naylor

2024 Week 48 In NJOY v VMR, the UPC Central Division Paris revoked VMR’s patent EP 3456214 B2 on 27 November 2024. The patent was held to be obvious, despite being maintained in amended form by the ...

UPC Weekly - UPC finds infringement using a doctrine of equivalents

UPC Weekly - UPC finds infringement using a doctrine of equivalents

by Matthew Naylor

2024 Week 47 Back in June 2024 (UPC Weekly 2024 week 23), we set out a few “known unknowns” – important developments in UPC case law that we expected to come in due course. New UPC decision Plant-e v ...

Resistance is futile – how new tech tackles AMR

Resistance is futile – how new tech tackles AMR

by Emily Lythell

Antimicrobial resistance (AMR) refers to the ability of microorganisms—bacteria, viruses, fungi, and parasites—to evolve and resist the effects of drugs that once effectively killed or inhibited ...

UPC Weekly - UPC dials up the advantages for patentees

UPC Weekly - UPC dials up the advantages for patentees

by Matthew Naylor

2024 Week 46 We report this week on two new UPC decisions that make the UPC an even more attractive choice for patent holders seeking to enforce their European patents. The headlines are that: (i) ...

Cambiotics: a novel treatment for PFAS ‘forever chemicals’

Cambiotics: a novel treatment for PFAS ‘forever chemicals’

by Eliot Ward

PFAS are toxic pollutants causing health problems globally. There is currently no treatment. Now a Danish startup is producing a probiotic, which it claims, flushes out the toxins via natural ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.